Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 756

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 756
---
10,466 | ​ |   |  50,288 | ​ |   |  -18,230 |
| Cash, cash equivalents and restricted cash at beginning of period                                                           | ​ |                         |   64,149 | ​ |   |  13,861 | ​ |   |   32,091 |
| Cash, cash equivalents and restricted cash at end of period                                                                 | ​ | $                       |   53,683 | ​ | $ |  64,149 | ​ | $ |   13,861 |
| Noncash investing and financing activities                                                                                  | ​ | ​                       |        ​ | ​ | ​ |       ​ | ​ |   |          |
| Accrual for leasehold improvements                                                                                          | ​ | $                       |      778 | ​ | $ |       — | ​ | $ |        — |

See Notes to Consolidated Financial Statements.

F-39

<div align='center'>CARA THERAPEUTICS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(amounts in thousands, except share and per share data)</div>

1. Business Cara Therapeutics, Inc., or the Company, is a development-stage biopharmaceutical corporation formed on July 2, 2004 . The Company is leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s primary activities to date have been organizing and staffing the Company, developing its lead product and product candidates, including conducting preclinical studies and clinical trials of difelikefalin-based product candidates, and raising capital. In August 2021, the Company received U.S. Food and Drug Administration, or FDA, approval for KORSUVA ® (difelikefalin) injection, or KORSUVA injection, for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Commercial launch of KORSUVA injection began in the United States in April 2022 and the Company began recording the associated profit-sharing revenues in the second quarter of 2022. In April 2022, the European Commission granted marketing authorization to difelikefalin injection under the brand name Kapruvia® (difelikefalin), or Kapruvia, for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. The marketing authorization approved Kapruvia for use in all member states of the European Union, or EU